H.G. Meerpohl

1.8k total citations
27 papers, 1.1k citations indexed

About

H.G. Meerpohl is a scholar working on Oncology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, H.G. Meerpohl has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Surgery and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in H.G. Meerpohl's work include Cancer Treatment and Pharmacology (11 papers), Ovarian cancer diagnosis and treatment (5 papers) and HER2/EGFR in Cancer Research (5 papers). H.G. Meerpohl is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Ovarian cancer diagnosis and treatment (5 papers) and HER2/EGFR in Cancer Research (5 papers). H.G. Meerpohl collaborates with scholars based in Germany, Switzerland and Estonia. H.G. Meerpohl's co-authors include Marie‐Luise Lohmann‐Matthes, Herbert Fischer, Andreas du Bois, Jalid Sehouli, H Engler, G. W. Löhr, Wolfram Brugger, Reinhard Andreesen, Stefan W. Krause and Carmen Scheibenbogen and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Immunology and European Journal of Cancer.

In The Last Decade

H.G. Meerpohl

26 papers receiving 1.0k citations

Peers

Countries citing papers authored by H.G. Meerpohl

Since Specialization

Citations

This map shows the geographic impact of H.G. Meerpohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.G. Meerpohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.G. Meerpohl more than expected).

Fields of papers citing papers by H.G. Meerpohl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.G. Meerpohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.G. Meerpohl. The network helps show where H.G. Meerpohl may publish in the future.

Co-authorship network of co-authors of H.G. Meerpohl

This figure shows the co-authorship network connecting the top 25 collaborators of H.G. Meerpohl. A scholar is included among the top collaborators of H.G. Meerpohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.G. Meerpohl. H.G. Meerpohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial 2010 ·Journal of Clinical Oncology ·Michael Untch, M Muscholl, Sergei Tjulandin, W. Jonat, H.G. Meerpohl, Mikhail Lichinitser, Alexey Manikhas, Alexandra Coumbos, R. Kreienberg, Andreas du Bois, Nadia Harbeck, Christian Jackisch, Volkmar Müller, Matthias Pauschinger, Christoph Thomssen, Michaela Lehle, Olivier Catalani, Hans‐Joachim Lück	55
2	Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer 2010 ·Oncology ·Hans‐Joachim Stemmler, Nadia Harbeck, (unknown), (unknown), (unknown), Wolfgang Abenhardt, (unknown), Harald Sommer, H.G. Meerpohl, Marion Kiechle, Volker Heinemann	20
3	Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer 2010 ·Oncology ·Hans‐Joachim Stemmler, Nadia Harbeck, (unknown), (unknown), (unknown), Wolfgang Abenhardt, (unknown), Harald Sommer, H.G. Meerpohl, Marion Kiechle, Volker Heinemann	7
4	Diagnosis of breast cancer with infrared spectroscopy from serum samples 2010 ·Vibrational Spectroscopy ·Juergen Backhaus, Ralf Müeller, (unknown), (unknown), H.G. Meerpohl, (unknown), Peter Bugert	98
5	Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group 2010 ·Journal of Clinical Oncology ·Jalid Sehouli, Dirk Stengel, Philipp Harter, Christian Kurzeder, Antje Belau, Thomas Bogenrieder, Susanne Markmann, Sven� Mahner, Lothar Mueller, Ralf Lorenz, (unknown), Jochen Wilke, Andreas Kuznik, Gabriele Doering, A. Wischnik, Harald Sommer, H.G. Meerpohl, W. Schroeder, W. Lichtenegger, Guelten Oskay-Oezcelik	76
6	Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer 2007 ·Oncology ·(unknown), Hans‐Joachim Stemmler, (unknown), Peter A. Fasching, F. Melchert, H. Kölbl, Martina Stauch, P. Maubach, Anton Scharl, G Morack, H.G. Meerpohl, Benjamin Weber, (unknown), Volker Heinemann	20
7	Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m<sup>2</sup> Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer 2006 ·Oncology ·Salah‐Eddin Al‐Batran, H.G. Meerpohl, Gϋnter von Minckwitz, Akin Atmaca, Ulrich R. Kleeberg, Nadia Harbeck, (unknown), (unknown), Jalid Sehouli, Alexander Knuth, Elke Jäger	44
8	Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial 2006 ·Annals of Surgical Oncology ·Philipp Harter, Andreas du Bois, Maik Hahmann, Annette Hasenburg, Alexander Burges, Sibylle Loibl, M. Gropp, Jens Huober, Daniel Fink, W. Schröder, Karsten Muenstedt, Barbara Schmalfeldt, Guenter Emons, Jacobus Pfisterer, K. Wollschlaeger, H.G. Meerpohl, G. P. Breitbach, Berno Tanner, Jalid Sehouli	275
9	Anthracycline and trastuzumab in breast cancer treatment. 2004 ·PubMed ·Michael Untch, (unknown), Steffen Kahlert, (unknown), Holger Eidtmann, Andreas du Bois, H.G. Meerpohl, Christoph Thomssen, Nadia Harbeck, C Jackisch, R. Kreienberg, Günter Emons, D. Wallwiener, William H. Wiese, Gerhard Schäller, W. Kühn, M Muscholl, M. Pauschinger, Bernd Langer	6
10	Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer 2004 ·European Journal of Cancer ·Michael Untch, Holger Eidtmann, Andreas du Bois, H.G. Meerpohl, (unknown), Andreas D. Ebert, Nadia Harbeck, Christian Jackisch, (unknown), Günter Emons, D. Wallwiener, William H. Wiese, Jens‐Uwe Blohmer, K. Höffken, W. Kühn, Peter Reichardt, M Muscholl, M. Pauschinger, Bernd Langer, Hans‐Joachim Lück	39
11	Prospective investigation of the significance of cardiac markers, NT-pro Brain Natriuretic Peptide (NT-proBNP) and Troponin T (TnT), in the Hercules study of epirubicin/cyclophosphamide with or without trastuzumab (Herceptin®) 2004 ·European Journal of Cancer Supplements ·Bernd Langer, M Muscholl, M. Pauschinger, Christoph Thomssen, Holger Eidtmann, M. Untch, H.G. Meerpohl, Andreas du Bois, H. Wéber, Hans-Joachim Lueck	2
12	Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy 1999 ·Supportive Care in Cancer ·Andreas du Bois, Markus P. Schlaich, Hans‐Joachim Lück, (unknown), (unknown), (unknown), Thomas Bauknecht, H.G. Meerpohl	31
13	Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. 1996 ·PubMed ·Hans‐Joachim Lück, Christoph Thomssen, Andreas duBois, B. Lisboa, Michael Untch, H. Kühnle, G. Konecny, F. Jänicke, H.G. Meerpohl, Christoph Lindner, (unknown), (unknown)	21
14	Pathophysiology, Severity, Pattern, and Risk Factors for Carboplatin-induced Emesis 1996 ·Oncology ·Andreas du Bois, Werner Vach, Marion Kiechle, (unknown), H.G. Meerpohl	16
15	Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. 1990 ·PubMed ·Reinhard Andreesen, Carmen Scheibenbogen, Wolfram Brugger, Stefan W. Krause, H.G. Meerpohl, H.-G. Leser, H Engler, G. W. Löhr	170
16	Das Rezidiv in der gynäkologischen Onkologie 1990 ·H.G. Meerpohl, (unknown), (unknown)	1
17	Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer 1990 ·Cancer Chemotherapy and Pharmacology ·(unknown), H.G. Meerpohl, W. Eiermann, (unknown), Luigi Lenaz, W. Achterrath	21
18	Role of prostaglandins on the regulation of macrophage proliferation and cytotoxic functions 1986 ·Prostaglandins ·H.G. Meerpohl, Thomas Bauknecht	13
19	Mouse bone marrow‐cultured macrophage as indicator cells for mouse and human migration inhibitory factor (MIF) 1977 ·European Journal of Immunology ·Marie‐Luise Lohmann‐Matthes, Wolfgang Domzig, H.G. Meerpohl	7
20	Studies on the activation of mouse bone marrow‐derived macrophages by the macrophage cytotoxicity factor (MCF) 1976 ·European Journal of Immunology ·H.G. Meerpohl, Marie‐Luise Lohmann‐Matthes, Herbert Fischer	116

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact